EFFECT OF A METALLOTHIONEIN ANTISENSE OLIGONUCLEOTIDE ON EMBRYO DEVELOPMENT

被引:8
|
作者
PETERS, JM
DUNCAN, JR
WILEY, LM
RUCKER, RB
KEEN, CL
机构
[1] UNIV CALIF DAVIS,DEPT NUTR,DAVIS,CA 95616
[2] UNIV CALIF DAVIS,DEPT OBSTET & GYNECOL,DIV REPROD BIOL & MED,DAVIS,CA
[3] RHODES UNIV,DEPT BIOCHEM & MICROBIOL,GRAHAMSTOWN,SOUTH AFRICA
[4] UNIV CALIF DAVIS,DEPT INTERNAL MED,DAVIS,CA
关键词
PREIMPLANTATION DEVELOPMENT; EMBRYO; METALLOTHIONEIN; ANTISENSE DNA; CADMIUM TOXICITY; NUCLEOTIDE TOXICITY;
D O I
10.1016/0890-6238(94)00062-X
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The effect of a metallothionein (MT) antisense oligodeoxynucleotide (ODN) on mouse preimplantation embryo development was investigated. Preimplantation embryos were cultured for 72 h and examined following exposure to either an MT antisense or sense ODN. Blastocyst formation (cavitation) and embryo cell number were lower in embryos exposed to the MT antisense ODN than in controls or in embryos exposed to the MT sense ODN. In embryos cultured in medium containing free nucleotides, cavitation frequency was not affected, although mean embryo cell number was lower than in controls. Combined, this work shows that an antisense ODN against MT can significantly affect blastocyst formation of preimplantation embryos; some, but not all, of the observed effects on embryo cell number may have been due to nucleotide toxicity.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [31] Antisense oligonucleotide drug design
    Schiavone, N
    Donnini, M
    Nicolin, A
    Capaccioli, S
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (07) : 769 - 784
  • [32] Antisense oligonucleotide therapy for HCMV
    Manoharan, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 21 - CARB
  • [33] Antisense and/or Immunostimulatory Oligonucleotide Therapeutics
    Agrawal, Sudhir
    Kandimalla, Ekambar R.
    CURRENT CANCER DRUG TARGETS, 2001, 1 (03) : 197 - 209
  • [34] ANTISENSE OLIGONUCLEOTIDE STRATEGIES IN PHYSIOLOGY
    BAERTSCHI, AJ
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1994, 101 (1-2) : R15 - R24
  • [35] DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDE THERAPY AGAINST ZFTA-RELA EPENDYMOMA
    Laboe, Nicholas
    Gee, David
    Bertrand, Kelsey
    Agnihotri, Sameer
    Mack, Stephen
    NEURO-ONCOLOGY, 2024, 26
  • [36] Antisense oligonucleotide treatments for psoriasis
    White, PJ
    Atley, LM
    Wraight, CJ
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (01) : 75 - 81
  • [37] An antisense oligonucleotide to target the RAAS
    Fernández-Ruiz I.
    Nature Reviews Cardiology, 2021, 18 (8) : 544 - 544
  • [38] Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development
    Holmlund, JT
    Monia, BP
    Kwoh, TJ
    Dorr, FA
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1999, 1 (03) : 372 - 385
  • [39] Progress in antisense oligonucleotide therapeutic
    Crooke, ST
    Bennett, CF
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 : 107 - 129
  • [40] Antisense oligonucleotide therapy in urology
    Kausch, I
    Böhle, A
    JOURNAL OF UROLOGY, 2002, 168 (01): : 239 - 247